View the Webinar


This interactive webinar is a focused program that will highlight significant data presented at the 2012 Digestive Disease Week conference. Dr. Brian Feagan and Dr. William Sandborn will give an expert review of the significant clinical findings surrounding monitoring anti-TNF levels and antibodies and describe how they can be applied to today’s patient care. This post-conference webinar will focus on the science and clinical utility of advances in monitoring anti-TNF levels and antibodies in personalizing the management of patients with inflammatory bowel disease.

Educational Objectives

After successful completion of this program, participants should be able to:

  • Understand the clinical factors that may influence loss of response to anti-TNF therapies
  • Understand the impact and clinical utility of utilizing anti-TNF drug and antibody level monitoring assays for the personalized care of patients with IBD

Back to top


Welcome and introduction – brief overview of the webinar and introduction of the faculty
William J. Sandborn, MD

Presentation – Current unmet needs for novel diagnostics in patients with IBD treated with biologic therapy
William J. Sandborn, MD

Presentation – Immunogenicity, pharmacokinetics and therapeutic drug monitoring
Brian G. Feagan, MD

Concluding discussion and remarks – Lessons from DDW 2012: summary of abstracts presented on the significance of monitoring anti-TNF drug levels and anti-drug antibody levels to guide treatment decisions; discussion of additional key data presented at DDW on novel diagnostics to highlight the applicability of the findings presented to current clinical practice
Brian G. Feagan, MD and William J. Sandborn, MD

Back to top


*required fields

Back to top